CN108186660A - 一种消肿西药软膏 - Google Patents
一种消肿西药软膏 Download PDFInfo
- Publication number
- CN108186660A CN108186660A CN201810269385.XA CN201810269385A CN108186660A CN 108186660 A CN108186660 A CN 108186660A CN 201810269385 A CN201810269385 A CN 201810269385A CN 108186660 A CN108186660 A CN 108186660A
- Authority
- CN
- China
- Prior art keywords
- parts
- detumescence
- benzalkonium chloride
- western medicine
- medicine ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 239000002674 ointment Substances 0.000 title claims abstract description 23
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 32
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 29
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- -1 bagodryl hydrochloride Chemical compound 0.000 claims abstract description 19
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003276 erythromycin Drugs 0.000 claims abstract description 16
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 13
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract description 13
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 13
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 13
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000011187 glycerol Nutrition 0.000 claims abstract description 13
- 229960003128 mupirocin Drugs 0.000 claims abstract description 13
- 229930187697 mupirocin Natural products 0.000 claims abstract description 13
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims abstract description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 13
- 229960001309 procaine hydrochloride Drugs 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 12
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- UUVNGFJBAZPFSQ-UHFFFAOYSA-N 2,3-dichloro-5-fluorobenzoyl chloride Chemical class FC1=CC(Cl)=C(Cl)C(C(Cl)=O)=C1 UUVNGFJBAZPFSQ-UHFFFAOYSA-N 0.000 claims description 3
- FUNUTBJJKQIVSY-UHFFFAOYSA-N 2,4-Dichlorotoluene Chemical compound CC1=CC=C(Cl)C=C1Cl FUNUTBJJKQIVSY-UHFFFAOYSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims description 3
- 241000187563 Rhodococcus ruber Species 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 230000001546 nitrifying effect Effects 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 231100000397 ulcer Toxicity 0.000 abstract description 4
- 206010000269 abscess Diseases 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 230000001139 anti-pruritic effect Effects 0.000 description 5
- 239000003908 antipruritic agent Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 2
- 241000623906 Lytta vesicatoria Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229940075397 calomel Drugs 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- YCSMVPSDJIOXGN-UHFFFAOYSA-N CCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCC[Na] YCSMVPSDJIOXGN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241001113926 Gelsemium Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- WRLRISOTNFYPMU-UHFFFAOYSA-N [S].CC1=CC=CC=C1 Chemical compound [S].CC1=CC=CC=C1 WRLRISOTNFYPMU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- HTUMBQDCCIXGCV-UHFFFAOYSA-N lead oxide Chemical compound [O-2].[Pb+2] HTUMBQDCCIXGCV-UHFFFAOYSA-N 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N lead(II) oxide Inorganic materials [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种消肿西药软膏，包含如下重量份的原料组分制成：红霉素5～15份；环丙沙星20～30份；莫匹罗星10～20份；聚乙二醇8～15份；苯扎氯铵8～15份；三乙醇胺5～10份；甘油10～15份；月桂氮酮5～10份；尼泊金乙酯0.1～0.5份；十二烷基硫酸钠1～3份、苯扎氯铵5～15份；水杨酸甲酯5～10份；盐酸苯海拉明2～10份；盐酸普鲁卡因5～15份；水100～150份，本发明配方简明，具有促进溃疡创面愈合以及消除脓肿的作用，且本发明所述的软膏外观细腻易涂布，稠度适中，耐热，耐寒，见效迅速，疗程短，满足了现在的使用要求。
Description
技术领域
本发明涉及一种药膏，具体是一种消肿西药软膏。
背景技术
凡在体表或某些粘膜部位应用，具有杀虫止痒、消肿散结、化腐排脓、生肌收口、收敛止血的一些药物，称为外用药。外用药主要用于痈疽疮毒、瘰疬、疥癣、外伤、蛇虫咬伤、烫伤及五官疾患等。根据其不同功用，可将外用药分为消肿解毒药、排脓祛腐药、止血生肌药、燥湿杀虫止痒药及发泡药5类。①消肿解毒药。能消散肿毒，用于各种疮疡初起、肿势局限而未溃破者，以及蛇虫咬伤者。常用的消肿解毒药有木芙蓉叶、蓖麻籽、露蜂房等。②排脓祛腐药。能提脓拔毒、化腐蚀疮，促使疮疡内蓄脓毒早日排出、腐肉迅速脱落。用于疮疡脓成未溃，或瘰疬、结核、恶疮溃后脓毒未尽、腐肉不脱、胬肉突出、死肌、瘘管、窦道以及赘疣、息肉等。常用的排脓祛腐药有升药、降药、铅丹、砒石、硇砂、斑蝥等。③止血生肌药。能制止出血，促进新肉生长，加速疮口愈合。用于各种外伤出血，疮疡溃后腐肉已脱、脓水将尽之时，以及疮口久不收口者。常用的止血生肌药有儿茶、血竭、象皮等。④燥湿杀虫止痒药。能使皮肤溃疡及湿疹局部减少滋水渗出，还有防腐、杀虫、止痒之功。用于湿毒、湿疹浸淫不已，疮面糜烂、滋水渗出较多，以及疥疮、顽癣、瘾疹瘙痒等。常用的燥湿杀虫止痒药有蛇床子、木槿皮、松花粉、炉甘石、硼砂、白矾、硫黄、雄黄、密陀僧、轻粉等。⑤发泡药。能通过敷贴患处或穴位，使局部皮肤灼热疼痛，出现水泡。用于疟疾、哮喘、急性黄疸等。常用的发泡药主要为毛茛。
外用药多具有不同程度的毒性，制剂时应严格遵照一定的法度，以保证用药安全。毒药应谨慎使用，剂量不宜过大，尤其是剧毒药物，如水银、砒石、轻粉、斑蝥等，必须严格掌握剂量。对于创面过大的局部病变，药量亦不宜过多，以防因吸收过量而中毒。同时，还必须避免连续用药，以防蓄积中毒。一些刺激性较强的药物，不宜在头面、五官、黏膜、会阴等处应用，以免发生不良反应或其他损害。现在外用软膏种类很多，其中消肿类的软膏更是种类众多，其中大多都是中药提取物制备的，起效时间较长，疗程长，不能满足现在的使用要求。
发明内容
本发明的目的在于提供一种消肿西药软膏，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种消肿西药软膏，包含如下重量份的原料组分制成：红霉素5～15份；环丙沙星20～30份；莫匹罗星10～20份；聚乙二醇8～15份；苯扎氯铵8～15份；三乙醇胺5～10份；甘油10～15份；月桂氮酮5～10份；尼泊金乙酯0.1～0.5份；十二烷基硫酸钠1～3份、苯扎氯铵5～15份；水杨酸甲酯5～10份；盐酸苯海拉明2～10份；盐酸普鲁卡因5～15份；水100～150份。
作为本发明进一步的方案：包含如下重量份的原料组分制成：红霉素5份；环丙沙星25份；莫匹罗星15份；聚乙二醇10份；苯扎氯铵10份；三乙醇胺6份；甘油11份；月桂氮酮8份；尼泊金乙酯1.2份；十二烷基硫酸钠2份、苯扎氯铵2份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因7份；水120份。
作为本发明进一步的方案：包含如下重量份的原料组分制成：红霉素10份；环丙沙星20份；莫匹罗星18份；聚乙二醇12份；苯扎氯铵10份；三乙醇胺7份；甘油12份；月桂氮酮7份；尼泊金乙酯0.4份；十二烷基硫酸钠2份、苯扎氯铵7份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因10份；水100份。
作为本发明进一步的方案：包含如下重量份的原料组分制成：红霉素12份；环丙沙星22份；莫匹罗星20份；聚乙二醇10份；苯扎氯铵8份；三乙醇胺9份；甘油10份；月桂氮酮8份；尼泊金乙酯0.3份；十二烷基硫酸钠1份、苯扎氯铵6份；水杨酸甲酯7份；盐酸苯海拉明8份；盐酸普鲁卡因7份；水150份。
作为本发明进一步的方案：所述水为纯化水。
作为本发明进一步的方案：所述红霉素通过红色链丝菌培养液中提取、提纯和浓缩制得。
作为本发明进一步的方案：所述环丙沙星是从2,4-二氯甲苯开始，经硝化、还原、氟化、氯化、水解和酰氯化形成2,4-二氯-5氟苯甲酰氯，然后先后和丙酸二乙酯，对甲苯磺酸，原甲酸三乙酯，环丙胺反应后再环合得喹啉环，经水解，再引入哌嗪基制得的。
作为本发明进一步的方案：所述聚乙二醇为聚乙二醇400。
作为本发明进一步的方案：所述苯扎氯铵为氯化二甲基苄基烃铵的混合物。
作为本发明进一步的方案：所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
与现有技术相比，本发明的有益效果是：本发明配方简明，具有促进溃疡创面愈合以及消除脓肿的作用，且本发明所述的软膏外观细腻易涂布，稠度适中，耐热，耐寒，见效迅速，疗程短，满足了现在的使用要求。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明实施例中，一种消肿西药软膏，包含如下重量份的原料组分制成：红霉素5～15份；环丙沙星20～30份；莫匹罗星10～20份；聚乙二醇8～15份；苯扎氯铵8～15份；三乙醇胺5～10份；甘油10～15份；月桂氮酮5～10份；尼泊金乙酯0.1～0.5份；十二烷基硫酸钠1～3份、苯扎氯铵5～15份；水杨酸甲酯5～10份；盐酸苯海拉明2～10份；盐酸普鲁卡因5～15份；水100～150份。
包含如下重量份的原料组分制成：红霉素5份；环丙沙星25份；莫匹罗星15份；聚乙二醇10份；苯扎氯铵10份；三乙醇胺6份；甘油11份；月桂氮酮8份；尼泊金乙酯1.2份；十二烷基硫酸钠2份、苯扎氯铵2份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因7份；水120份。
包含如下重量份的原料组分制成：红霉素10份；环丙沙星20份；莫匹罗星18份；聚乙二醇12份；苯扎氯铵10份；三乙醇胺7份；甘油12份；月桂氮酮7份；尼泊金乙酯0.4份；十二烷基硫酸钠2份、苯扎氯铵7份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因10份；水100份。
包含如下重量份的原料组分制成：红霉素12份；环丙沙星22份；莫匹罗星20份；聚乙二醇10份；苯扎氯铵8份；三乙醇胺9份；甘油10份；月桂氮酮8份；尼泊金乙酯0.3份；十二烷基硫酸钠1份、苯扎氯铵6份；水杨酸甲酯7份；盐酸苯海拉明8份；盐酸普鲁卡因7份；水150份。
所述水为纯化水。
所述红霉素通过红色链丝菌培养液中提取、提纯和浓缩制得。
所述环丙沙星是从2,4-二氯甲苯开始，经硝化、还原、氟化、氯化、水解和酰氯化形成2,4-二氯-5氟苯甲酰氯，然后先后和丙酸二乙酯，对甲苯磺酸，原甲酸三乙酯，环丙胺反应后再环合得喹啉环，经水解，再引入哌嗪基制得的。
所述聚乙二醇为聚乙二醇400。
所述苯扎氯铵为氯化二甲基苄基烃铵的混合物。
所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
本发明配方简明，具有促进溃疡创面愈合以及消除脓肿的作用，且本发明所述的软膏外观细腻易涂布，稠度适中，耐热，耐寒，见效迅速，疗程短，满足了现在的使用要求。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (10)
1.一种消肿西药软膏，其特征在于，包含如下重量份的原料组分制成：红霉素5～15份；环丙沙星20～30份；莫匹罗星10～20份；聚乙二醇8～15份；苯扎氯铵8～15份；三乙醇胺5～10份；甘油10～15份；月桂氮酮5～10份；尼泊金乙酯0.1～0.5份；十二烷基硫酸钠1～3份、苯扎氯铵5～15份；水杨酸甲酯5～10份；盐酸苯海拉明2～10份；盐酸普鲁卡因5～15份；水100～150份。
2.根据权利要求1所述的消肿西药软膏，其特征在于，包含如下重量份的原料组分制成：红霉素5份；环丙沙星25份；莫匹罗星15份；聚乙二醇10份；苯扎氯铵10份；三乙醇胺6份；甘油11份；月桂氮酮8份；尼泊金乙酯1.2份；十二烷基硫酸钠2份、苯扎氯铵2份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因7份；水120份。
3.根据权利要求1所述的消肿西药软膏，其特征在于，包含如下重量份的原料组分制成：红霉素10份；环丙沙星20份；莫匹罗星18份；聚乙二醇12份；苯扎氯铵10份；三乙醇胺7份；甘油12份；月桂氮酮7份；尼泊金乙酯0.4份；十二烷基硫酸钠2份、苯扎氯铵7份；水杨酸甲酯6份；盐酸苯海拉明3份；盐酸普鲁卡因10份；水100份。
4.根据权利要求1所述的消肿西药软膏，其特征在于，包含如下重量份的原料组分制成：红霉素12份；环丙沙星22份；莫匹罗星20份；聚乙二醇10份；苯扎氯铵8份；三乙醇胺9份；甘油10份；月桂氮酮8份；尼泊金乙酯0.3份；十二烷基硫酸钠1份、苯扎氯铵6份；水杨酸甲酯7份；盐酸苯海拉明8份；盐酸普鲁卡因7份；水150份。
5.根据权利要求1所述的消肿西药软膏，其特征在于，所述水为纯化水。
6.根据权利要求1所述的消肿西药软膏，其特征在于，所述红霉素通过红色链丝菌培养液中提取、提纯和浓缩制得。
7.根据权利要求1所述的消肿西药软膏，其特征在于，所述环丙沙星是从2,4-二氯甲苯开始，经硝化、还原、氟化、氯化、水解和酰氯化形成2,4-二氯-5氟苯甲酰氯，然后先后和丙酸二乙酯，对甲苯磺酸，原甲酸三乙酯，环丙胺反应后再环合得喹啉环，经水解，再引入哌嗪基制得的。
8.根据权利要求1所述的消肿西药软膏，其特征在于，所述聚乙二醇为聚乙二醇400。
9.根据权利要求1所述的消肿西药软膏，其特征在于，所述苯扎氯铵为氯化二甲基苄基烃铵的混合物。
10.根据权利要求1所述的消肿西药软膏，其特征在于，所述月桂氮酮为1-正十二烷基氮杂环庚烷-2-酮。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810269385.XA CN108186660A (zh) | 2018-03-29 | 2018-03-29 | 一种消肿西药软膏 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810269385.XA CN108186660A (zh) | 2018-03-29 | 2018-03-29 | 一种消肿西药软膏 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108186660A true CN108186660A (zh) | 2018-06-22 |
Family
ID=62596307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810269385.XA Pending CN108186660A (zh) | 2018-03-29 | 2018-03-29 | 一种消肿西药软膏 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108186660A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| CN114632139A (zh) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | 一种红霉素药膏及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308210A1 (en) * | 1987-09-16 | 1989-03-22 | Patrick A. Beauchamp | Topical treatment of diseased skin disorders |
| CN106880725A (zh) * | 2016-12-21 | 2017-06-23 | 毛嘉明 | 一种治疗淤血型肩周炎的贴膏剂 |
| CN107233368A (zh) * | 2017-06-22 | 2017-10-10 | 广东药科大学 | 一种拔脓消肿中药外用软膏及其制备方法 |
-
2018
- 2018-03-29 CN CN201810269385.XA patent/CN108186660A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308210A1 (en) * | 1987-09-16 | 1989-03-22 | Patrick A. Beauchamp | Topical treatment of diseased skin disorders |
| CN106880725A (zh) * | 2016-12-21 | 2017-06-23 | 毛嘉明 | 一种治疗淤血型肩周炎的贴膏剂 |
| CN107233368A (zh) * | 2017-06-22 | 2017-10-10 | 广东药科大学 | 一种拔脓消肿中药外用软膏及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 陈斌: "《常见皮肤病用药与食疗》", 31 October 2013, 金盾出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| CN114632139A (zh) * | 2022-04-02 | 2022-06-17 | 北京双吉制药有限公司 | 一种红霉素药膏及其制备方法 |
| CN114632139B (zh) * | 2022-04-02 | 2023-04-07 | 北京双吉制药有限公司 | 一种红霉素药膏及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101879283B (zh) | 一种用于皮肤外伤的喷膜制剂及制备方法 | |
| CN103341203B (zh) | 一种药用敷料、药用敷料制作方法及敷料贴的制作方法 | |
| JP2019513136A5 (zh) | ||
| CN104257970B (zh) | 一种外用跌打药膏 | |
| HRP20201290T1 (hr) | Novi izooblici tripsina i njihova upotreba | |
| CN108186660A (zh) | 一种消肿西药软膏 | |
| CN102766548A (zh) | 一种抗菌消炎、护肤美容的药皂及其制备方法 | |
| CN104666496A (zh) | 一种薄荷膏及其制备工艺 | |
| CN102579483A (zh) | 一种治疗轻度烧伤的乳液擦剂及其制备方法 | |
| CN104056299A (zh) | 一种液体护创膜及制备方法 | |
| CN101658590A (zh) | 具有活血消肿功能的中药膏剂 | |
| CN101028365B (zh) | 一种治疗烧、烫伤的药物及其制备方法 | |
| Wong et al. | Scar-free healing of wounds resulting commonly from domestic accidents | |
| CN105287628A (zh) | 一种治疗脚气足癣药的制备方法 | |
| CN104435566A (zh) | 一种治疗动物创伤外用药物及制备方法 | |
| CN105832817B (zh) | 吡咯喹啉醌在制备用于治疗烧伤、烫伤和创伤方面的药物组合物中的应用 | |
| CN103893553B (zh) | 一种创面用中药复方膜剂及其制备方法 | |
| CN112121146A (zh) | 一种用于皮肤创伤的外用凝胶剂及其制备方法 | |
| Pudale | Homoeopathic Miasmatic Approach in Dermatitis | |
| CN106491929A (zh) | 一种鼻炎喷雾剂 | |
| RU2173155C1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
| CN102133324B (zh) | 一种治疗表皮烧烫伤的药膏 | |
| RU2256441C1 (ru) | Мазь для лечения ожогов, гнойных и инфицированных ран различной этиологии и способ лечения ожогов, гнойных и инфицированных ран | |
| CN102552970B (zh) | 湿疹皮炎湿敷贴 | |
| CN105168208A (zh) | 一种退热退烧及防暑降温的外用药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180622 |